Friday, June 17, 2016

UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial

LONDON, June 17 (Reuters) - British drug developer Scancell

has suspended dosing in a cancer clinical trial because

of quality problems with an immunotherapy treatment, wiping more

than a quarter...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)